可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

BSA载药微囊的制备、表征及体外释放行为

采用复乳法-液中干燥法制备了一系列含有牛血清蛋白(BSA)的聚乙二醇-b-聚(6-(乙酸苄酯)-ε-己内酯-co-ε-己内酯(PEBCL)微囊.分别研究了聚合物结构以及制备条件对微囊粒径、载药量和包封率的影响,同时研究了载药微囊在pH=7.4的磷酸盐缓冲溶液中的体外释放行为.研究表明:微囊的平均粒径13～30 μm,微囊对BSA的载药量和包封率分别最高可以达到14.18%和75.90%,药物的释放行为可控,PEBCL微囊作为蛋白质类药物载体有望在临床上获得应用.     

适配子修饰靶向PLGA纳米基因载体的构建

化学合成了功能性三嵌段复合物乳酸乙醇酸共聚物-聚乙二醇-适配子(PLGA-PEG-Apt)。使用双乳化挥发法制备包裹DNA片段的PLGA-PEG-Apt新型纳米基因药物载体,表征检测显示:制备的纳米基因载体粒径为(225.2±8.1)nm,Zeta电位约(-35.5±-3.3)mV。扫描电子显微镜下纳米颗粒形态呈圆形,表面光滑,粒径分布较均匀。纳米粒子对TFO的包封率为(25.4±3.1)%(n=3),载药量为(1.34±0.16)μg/mg。体外释放实验研究结果显示持续释放过程达23 d,且PLGA-PEG-Apt纳米粒子呈突释之后的持续缓释过程。细胞水平实验结果显示,A10适配子修饰的纳米基因载体能更多进入靶向的前列腺癌细胞株,进而发挥其抗前列腺癌增殖的作用。该研究成功制备了靶向PLGA纳米基因载体,结果满意。     

黄体酮纳米胶束构建及体外释放行为

为了制备可缓释释放的黄体酮纳米胶束新剂型,构建了两嵌段聚合物载体聚乙二醇-聚丙烯基缩水甘油醚(PEG-PAGE),组装成胶束,对黄体酮担载,考察不同条件下的载药量和包封率,筛选出最佳比例,并进行体外释放研究。 结果表明,该胶束能够担载黄体酮,载药量为4.26%,包封率为21.30%,48 h内累计释放达61.31%,能够有效地延缓黄体酮的释放,为黄体酮纳米剂型的开发提供了实验和技术参考。     

5-氟尿嘧啶/壳聚糖载药纳米微球的制备及性能

以三聚磷酸钠为交联剂,采用离子交联法制备了5-氟尿嘧啶/壳聚糖纳米微球,评价其性能、体外释药性能及对人肺癌细胞GLC-82的体外杀伤效应,并通过Zeta电位和红外光谱分析载药纳米微球形成机理.结果表明,所制备的5-Fu/CS纳米微球平均包封率为32.3%,平均载药量为25.6%,平均粒径为253nm,平均zeta电势为+8.38mV,成球性及分散性良好.CS载药纳米微球具有缓释性能,体外释药行为符合双向动力学规律.在体外作用72h,CS载药纳米微球对人肺癌细胞GLC-82的杀伤率达66.6%,杀伤效果明显优于5-Fu对照组.     

PLGA-磷酸钙复合载药纳米粒的制备

利用聚氧乙烯硬脂酸酯(Brij78)和帕米膦酸二钠制备新型表面活性剂Pa-Brij78,以此为表面活性剂,聚乳酸-羟基乙酸共聚物(poly(lactic-co-glycolic acid),PLGA)为油相,采用水包油包水的微乳液法制备载卵清蛋白(ovalbumin,OVA)的表面带有磷酸根的PLGA纳米粒,再用共沉淀法在其表面修饰一层磷酸钙,并装载寡核苷酸Cp G,形成一种核-壳结构的复合载药纳米粒Cp G/Ca P/PLGA(OVA).通过动态光散射粒度仪、扫描电子显微镜(SEM)、透射电子显微镜(TEM)、X射线衍射(XRD)对纳米粒进行表征,并测定OVA、Cp G的载药量、包封率.结果表明以Pa-Brij78为表面活性剂制备的PLGA(OVA)纳米粒确实能被磷酸钙修饰,粒径增大40~60 nm,表面变粗糙,XRD测得该磷酸钙层的主要存在形式为Ca3(PO4)2.OVA平均载药量为5%,包封率大于80%;Cp G平均载药量为0.47%,平均包封率为89.9%.     

微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

顺铂温敏载药粒子的制备表征

制备了顺铂温敏载药纳米粒子，表征其相关性质并考察不同温度下对体外肿瘤细胞的生长抑制作用。制备的两亲嵌段聚合物在水溶液中自发形成胶束结构并包裹顺铂，测定顺铂载药粒子的结构、形态、粒径及包封率、载药量、晶体状态等特性，并对顺铂的体外释放以及不同细胞系体外毒性也做了研究。载药粒子粒径为83.3 ± 4.3 nm，载药量为37.8%，包封率为77.8%。血清中相变温度39.3 ℃。载药颗粒在单纯化疗时细胞抑制率较小，加热后抑制作用明显增加(P<0.01)，与游离药物相近(P>0.5)。顺铂载药纳米粒子具有较好的温控特性，为顺铂在肿瘤热靶向治疗中的应用提供了一条新的途径。     

In vitro Studies of Chitosan-based Muitifunctional Drug Delivery Nanosystem

制备了一种壳聚糖基多功能纳米药物载体系统,并探讨了其体外释药性质.合成了甲氨蝶呤-壳聚糖偶联物(MTX-CS),甲氨喋呤(MTX)的取代度为6.3％;MTX-CS具有两亲性,在水性介质中能自组装形成纳米粒子,平均粒径为(269.5±18.3) nm,zeta电位为(25.7±0.9) mV.MTX-CS纳米粒子能有效包载抗血管生成药Combretastatin A-4(CA-4),当药物/载体材料投料比为1∶4时,载药量为15.7％,包封率为62.8％.体外释放实验结果显示,CA-4释放较快,MTX释放缓慢,有利于发挥2种药物的协同抗肿瘤作用.     

高效氯氰菊酯微胶囊的制备、表征及释放性能

以高效氯氰菊酯为芯材, 乙基纤维素为壁材, 采用溶剂蒸发法制备了微胶囊, 并对其理化性能进行表征, 通过单因素实验研究了工艺参数对微胶囊外观形貌、 粒径大小及分布、 包封率、 载药量和缓释性能的影响. 结果表明, 乳化剂种类和剪切时间可以显著影响微胶囊的外观形貌; 随着乳化剂用量增大, 微胶囊粒径减小, 分布变窄, 当Tween-80用量从4%增加至8%时, 微胶囊平均粒径从59.9 μm减少到29.8 μm, 跨距也从1.21减少到0.72. 随着芯壁比(质量比)减小, 微胶囊粒径和包封率均逐渐增大, 载药量逐渐减小, 当芯壁比为1:1.75时, 包封率可以达到70%以上. 微胶囊释放动力学模型符合Ritger-Peppas模型(lgQ=lgk+nlgt); 平均粒径相近而载药量不同时, 初期载药量最小的样品释放速率慢, 累积释放率低; 载药量相近而平均粒径不同时, 粒径大的样品释放速率低, 累积释放率也低.     

Formulation of Cannabidiol in Colloidal Lipid Carriers

In this study, the general processability of cannabidiol (CBD) in colloidal lipid carriers was investigated. Due to its many pharmacological effects, the pharmaceutical use of this poorly water-soluble drug is currently under intensive research and colloidal lipid emulsions are a well-established formulation option for such lipophilic substances. To obtain a better understanding of the formulability of CBD in lipid emulsions, different aspects of CBD loading and its interaction with the emulsion droplets were investigated. Very high drug loads (>40% related to lipid content) could be achieved in emulsions of medium chain triglycerides, rapeseed oil, soybean oil and trimyristin. The maximum CBD load depended on the type of lipid matrix. CBD loading increased the particle size and the density of the lipid matrix. The loading capacity of a trimyristin emulsion for CBD was superior to that of a suspension of solid lipid nanoparticles based on trimyristin (69% vs. 30% related to the lipid matrix). In addition to its localization within the lipid core of the emulsion droplets, cannabidiol was associated with the droplet interface to a remarkable extent. According to a stress test, CBD destabilized the emulsions, with phospholipid-stabilized emulsions being more stable than poloxamer-stabilized ones. Furthermore, it was possible to produce emulsions with pure CBD as the dispersed phase, since CBD demonstrated such a pronounced supercooling tendency that it did not recrystallize, even if cooled to −60 °C.     

Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification

Nanostructured lipid carriers (NLC) made from mixtures of solid and spatially incompatible liquid lipids were prepared by melt-emulsification. Their drug loading capacity and releasing properties of progesterone were compared with those of solid lipid nanoparticles (SLN), and the NLC prepared by solvent diffusion method. Monostearin (MS) and stearic acid (SA) were used as solid lipid, whilst the oleic acid (OA) was used as liquid lipid. Properties of carriers such as the particle size and its distribution, drug loading, drug encapsulation efficiency and drug release behavior were investigated. As a result, the drug encapsulation efficiencies were improved by adding the liquid lipid into the solid lipid of nanoparticles. The drug release behavior could be adjusted by the addition of liquid lipid, and the NLC with higher OA content showed the faster rate of drug releasing. NLC had higher efficiency of encapsulation and slower rate of drug release than those of NLC prepared by solvent diffusion method. On the other hand, the NLC with higher drug loading was obtained, though the drug encapsulation efficiency was decreased slightly due to the increase of the amount of drug. The NLC modified with polyethylene glycol (PEG) was also prepared by using polyethylene glycol monostearate (PEG-SA). It was observed that the incorporation of PEG-SA reduced the drug encapsulation efficiency, but increased the rate of drug release. A sample with almost complete drug release in 24 h was obtained by modifying with 1.30 mol% PEG-SA. It indicated that the modified NLC was a potential drug delivery system for oral administration.     

Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification

Nanostructured lipid carriers (NLC) made from mixtures of solid and spatially incompatible liquid lipids were prepared by melt-emulsification. Their drug loading capacity and releasing properties of progesterone were compared with those of solid lipid nanoparticles (SLN), and the NLC prepared by solvent diffusion method. Monostearin (MS) and stearic acid (SA) were used as solid lipid, whilst the oleic acid (OA) was used as liquid lipid. Properties of carriers such as the particle size and its distribution, drug loading, drug encapsulation efficiency and drug release behavior were investigated. As a result, the drug encapsulation efficiencies were improved by adding the liquid lipid into the solid lipid of nanoparticles. The drug release behavior could be adjusted by the addition of liquid lipid, and the NLC with higher OA content showed the faster rate of drug releasing. NLC had higher efficiency of encapsulation and slower rate of drug release than those of NLC prepared by solvent diffusion method. On the other hand, the NLC with higher drug loading was obtained, though the drug encapsulation efficiency was decreased slightly due to the increase of the amount of drug. The NLC modified with polyethylene glycol (PEG) was also prepared by using polyethylene glycol monostearate (PEG-SA). It was observed that the incorporation of PEG-SA reduced the drug encapsulation efficiency, but increased the rate of drug release. A sample with almost complete drug release in 24 h was obtained by modifying with 1.30 mol% PEG-SA. It indicated that the modified NLC was a potential drug delivery system for oral administration.     

Physicochemical Investigation of Engineered Nanosuspensions Containing Model Drug,Lansoprazole

Lansoprazole is a proton-pump inhibitor used in treatment of gastric ulcers, gastroesophageal reflux disease (GERD), and Zollinger–Ellison syndrome. The objective of the study was physicochemical investigation and comparative characterization of nanosuspensions of lansoprazole by complexing with β-cyclodextrin and β-cyclodextrin-based nanosponges to enhance its solubility and stability. Inclusion complexes of lansoprazole with β-cyclodextrin and nanosponges were prepared by physical method and polymer condensation method, respectively. Particle size, zeta potential, encapsulation efficiency, in vitro release, FTIR, and Differential Scanning Calorimeter (DSC) studies were used as characterization parameters. The average particle size of lansoprazole nanoparticles was found to be in the range of 178.7 ± 6.39 nm to 204.9 ± 2.91 nm. The high zeta potential values were attained to ensure a high-energy barrier and favor a good stability of nanosuspensions. In vitro release study showed the controlled release of lansoprazole, which was more satisfactory than individual drug. FTIR spectroscopy showed that there was interaction of cyclodextrin and its nanosponges with drug. DSC study revealed that drug was involved in complexion with cyclodextrin and nanosponges. Solubility and stability of lansoprazole were remarkably improved by inclusion complexation. Based on these findings, it can be concluded that engineered nanosuspension of lansoprazole is a promising carrier for nanoparticulate drug delivery in gastric ulcer.     

A green chemistry approach towards synthesizing hydrogel for sustained ocular delivery of brinzolamide: In vitro and ex vivo evaluation

Brinzolamide is a carbonic anhydrase inhibitor used in the eye drop form for the treatment of glaucoma. It requires frequent dosing to attain therapeutic concentration. Therefore, this study aimed to prepare sustained ocular drug delivery of brinzolamide. The objective of the study was to prepare a hydrogel loaded with a nanostructured lipid carrier (NLC) of brinzolamide. The hydrogel was prepared by a green synthesis approach using genipin as a natural crosslinking agent and polymers such as carboxymethyl chitosan and poloxamer 407. The melt emulsification-ultra sonication method was used to prepare a nanostructured lipid carrier of brinzolamide, which was loaded into a hydrogel using a swelling and loading method. The NLC formulation has shown small particle sizes of 111.20 ?± ?2.15 ?nm, polydispersity index of 0.280 ?± ?0.005 and % entrapment efficiency of 82.16% ?± ?0.14%. The NLC-loaded hydrogels of brinzolamide formulations were studied for swelling properties and showed temperature and pH-responsive swelling behavior. The optimized hydrogel formulation has been studied for in vitro drug release and showed drug release for a longer duration (24 ?h) than marketed eye drops (8 ?h). In an ex vivo study, hydrogel formulations showed transcorneal permeability 4.54 times greater than marketed eye drops. The hydrogel formulation of brinzolamide produced by the green synthesis method has shown sustained-release properties with no sign of ocular irritation. Hence, the hydrogel of brinzolamide-loaded NLC would be the potential drug delivery approach in the near future for sustained ocular drug delivery in glaucoma management.     

Ciprofloxacin Loaded Alginate/Chitosan and Solid Lipid Nanoparticles,Preparation, and Characterization

The aim of the present study was to develop controlled drug delivery systems based on nanotechnology. Two different nanocarriers were selected, chitosan-alginate nanoparticles as hydrophilic and solid lipid nanoparticles as lipophilic carriers. Nanoparticles were prepared and characterized by evaluating particle size, zeta potential, SEM pictures, DSC thermograms, percentage of drug loading efficiency, and drug release profile. The particle size of SLNs and Chi/Alg nanoparticles was 291 ± 5 and 520 ± 16. Drug loading efficiency of Chi/Alg and SLN particles were 68.98 ± 5.5% and 88 ± 4.5%. The drug release was sustained with chitosan-alginate system for about 45 hours whereas for SLNs >98% of the drug was released in 2 hours. Release profile did not change significantly after freeze drying of particles using cryoprotector. Results suggest that under in vitro condition chitosan/alginate systems can act as promising carriers for ciprofloxacin and may be used as an alternative system in sustained delivery of ciprofloxacin.     

Influence of lipid content and dilution on properties and stability of nanostructured lipid carriers (NLCs) prepared from rambutan (Nephelium lappaceum L.) kernel fat and evaluation of their β-carotene loading capacity

Abstract

The effects of lipid content and dilution on the properties and stability of nanostructured lipid carriers (NLCs) prepared from rambutan (Nephelium lappaceum L.) kernel fat were investigated. The β-carotene-loading capacity of the NLCs was also evaluated. NLCs containing various lipid phase concentrations (5, 10, and 15?wt%) were prepared using Tween 80 as the emulsifier with a lipid to emulsifier weight ratio of 1:0.2. The results showed that an increase in the lipid content up to 15?wt% had no effect on the zeta-potential, particle size and polydispersity index but resulted in a higher particle density. All samples showed no phase separation during storage at 25?°C for 28?days; however, the relative recrystallization index (RRI) increased. Dilution of concentrated NLC (15?wt%) to a lower lipid content (5 and 10?wt%) produced no differences in the particle characteristics and stability during storage. NLCs loaded with β-carotene at different concentrations (0, 0.5, and 1?wt% of the lipid phase) exhibited desirable characteristics and had high encapsulation efficiency (～97%) over 28?days of storage. These results demonstrated that NLC prepared from rambutan kernel fat can be used to entrap lipophilic bioactive components which could be used as ingredients in functional food products.     

Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables

This study aimed to prepare solid lipid nanoparticles (SLNs) of a hydrophobic drug, tretinoin, by emulsification-ultrasonication method. Solubility of tretinoin in the solid lipids was examined. Effects of process variables were investigated on particle size, polydispersity index (PI), zeta potential (ZP), drug encapsulation efficiency (EE), and drug loading (L) of the SLNs. Shape and surface morphology of the SLNs were investigated by cryogenic field emission scanning electron microscopy (cryo-FESEM). Complete encapsulation of drug in the nanoparticles was checked by cross-polarized light microscopy and differential scanning calorimetry (DSC). Crystallinity of the formulation was analyzed by DSC and powder X-ray diffraction (PXRD). In addition, drug release and stability studies were also performed. The results indicated that 10mg tretinoin was soluble in 0.45±0.07 g Precirol? ATO5 and 0.36±0.06 g Compritol? 888ATO, respectively. Process variables exhibited significant influence in producing SLNs. SLNs with <120 nm size, <0.2 PI, >I30I mV ZP, >75% EE, and ～0.8% L can be produced following the appropriate formulation conditions. Cryo-FESEM study showed spherical particles with smooth surface. Cross-polarized light microscopy study revealed that drug crystals in the external aqueous phase were absent when the SLNs were prepared at ≤0.05% drug concentration. DSC and PXRD studies indicated complete drug encapsulation within the nanoparticle matrix as amorphous form. The drug release study demonstrated sustained/prolonged drug release from the SLNs. Furthermore, tretinoin-loaded SLNs were stable for 3 months at 4°C. Hence, the developed SLNs can be used as drug carrier for sustained/prolonged drug release and/or to improve oral absorption/bioavailability.     

Core–shell nanoparticles of carboxy methyl cellulose and compritol-PEG for antiretroviral drug delivery

Multi-functional nanoparticles hold great promise for the effective treatment of many diseases. Zidovudine a commonly used anti-HIV drug, requires a delivery system for more effective treatment of AIDS. The present study focuses on the development of anti-viral drug-loaded hybrid nanoparticles (LPNs) of lipid and polymer consisting of carboxy methyl cellulose—zidovudine (AZT) core enclosed by a compritol (Comp)-polyethylene glycol shell. The characterization of drug loaded LPNs was done using TEM, DLS and FT-IR analysis. The drug loading efficiency, drug release, blood compatibility, MTT assay and cell uptake studies were carried out using the LPNs. The synthesized nanoparticles exhibited core–shell morphology with an average size of 161.65 ± 44.06 nm; the LPN also demonstrated 82% drug encapsulation efficiency with slow drug release behaviour. The hybrid nanoparticles were found to be blood compatible and non toxic. The rhodamine-labeled hybrid nanoparticles were also found to effectively enter the brain cells. The novel hybrid drug delivery system shows controlled drug release, biocompatibility and high drug loading efficiency. These LPNs obtained from natural polymers can provide an excellent platform for designing systems for targeted drug delivery.     

不同相对分子质量羟乙基纤维素对甲维盐微胶囊制备的影响

采用原位聚合法以三聚氰胺-甲醛树脂为壁材制备了甲维盐微胶囊。 探讨了不同黏均相对分子质量羟乙基纤维素作为乳化剂对微胶囊表面形貌、粒径及其分布、包覆率与载药量的影响,对使用不同黏均相对分子质量羟乙基纤维素作为乳化剂制备的微胶囊的释放性能进行了表征。 结果表明,以相对分子质量较小的羟乙基纤维素制备的微胶囊外形规则、致密且无黏连现象。 随羟乙基纤维素黏均相对分子质量的增加所得微胶囊的平均粒径及粒径分布逐渐增大,包覆率与载药量逐渐减小。 释放性能的研究表明,采用相对分子质量较小的羟乙基纤维素制备的微胶囊的释放性能较好。